Margot Anne Chima MD FAAD (She/Her)
Cosmetic Dermatology
Margot Chima at Mount Sinai Dermatology
Join to view full profile
1424 Madison Ave.New York, NY 10029
Phone+1 212-241-6500
Dr. Chima is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Margot Chima is a Dermatologist based in New York, specializing in Dermatology with a subspecialty in Cosmetic Dermatology. She completed her Dermatology training at the Icahn School of Medicine at Mount Sinai, where she also underwent a Dermatopharmacology fellowship. Currently, she practices at Treiber Dermatology Associates and The Dermatology Specialists and serves as a Clinical Instructor at the Icahn School of Medicine. Her clinical research focuses on conditions such as eczema and nail disorders, and she has contributed to multiple publications on topics including alopecia areata and vitiligo. Dr. Chima has been involved in various clinical trials relating to atopic dermatitis and other dermatological conditions.
Education & Training
Icahn School of Medicine at Mount SinaiChief Residency, Dermatology, 2021 - 2022- Icahn School of Medicine at Mount SinaiResidency, Dermatology, 2019 - 2022
- Icahn School of Medicine at Mount SinaiFellowship, Dermatopharmacology, 2017 - 2019
University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 2016 - 2017
University of Nebraska College of MedicineClass of 2016
Certifications & Licensure
NY State Medical License 2017 - 2028
American Board of Dermatology Dermatology
Clinical Trials
- A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) Start of enrollment: 2012 May 18
- A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) Start of enrollment: 2015 May 26
- Secukinumab for Treatment of Atopic Dermatitis
Publications & Presentations
PubMed
- 44 citationsScalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata.Yael Renert-Yuval, Ana B Pavel, Ester Del Duca, Paola Facheris, Angel D Pagan
Allergy. 2023-04-01 - 11 citationsApremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in ...Hee J Kim, Ester Del Duca, Ana B Pavel, Giselle K Singer, Brian J Abittan
Archives of Dermatological Research. 2023-03-01 - 31 citationsSecukinumab responses vary across the spectrum of congenital ichthyosis in adults.Rachel Lefferdink, Stephanie M Rangel, Margot Chima, Erin Ibler, Ana B Pavel
Archives of Dermatological Research. 2023-03-01
Books/Book Chapters
Grant Support
- Acetylation as a novel post-translational modification of MafACOLUMBIA UNIVERSITY HEALTH SCIENCES2024–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
